Medicus Pharma Reports ~80% Overall Response Rate, 73% Clinical Clearance From Clinical Validation Of Phase 2 SkinJect Dataset
Benzinga Newsdesk 7 months ago
News
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today reported independent clinical validation of its Phase 2 SkinJect® dataset from Dr. Babar Rao, principal investigator of the SKNJCT-003 study and a globally recognized dermatology key opinion leader.
The 200µg cohort at Day 57 demonstrated the highest observed activity in the study, including:
- ~80% overall response rate
- 73% clinical clearance
- 40% histological clearance
- Evidence of continued biological activity over time